美國
證券交易委員會
華盛頓,特區。20549
表格
根據1934年證券交易法第13或15(d)條規定的過渡報告
截至季度結束
要麼
根據1934年證券交易法第13或15(d)條規定的過渡報告
在從___到____的過渡期間
委員會文件號
(公司章程中指定的準確公司名稱)
(成立州或其他管轄區) | (美國國稅局僱主號碼) | |
〇 結構或組織形式的設立) | (主要 執行人員之地址) |
(總部地址) (郵政編碼)
根據交易所法規(17 CFR 240.14a-12)第14a-12規定的招股材料
(公司更名、更改地址和更改財年情況的以往名稱、以前地址和以前財年,如與上次報告有所改變)
根據法案第12(b)節註冊的證券:
每一類別的名稱 | 交易符號 | 在每個交易所註冊的名稱 | ||
不適用 | 不適用 | 不適用 |
請勾選標記以指示註冊者是否(1)在過去12個月內(或註冊者需要提交這些報告的更短時間內)已提交證券交易所法案第13或15(d)節要求提交的所有報告,及 (2)是否已被提交要求過去90天的提交要求所制約。
通過勾選圓圈表明註冊者是否在過去12個月內(或註冊者需要提交這些文件的較短期限內)已經遞交規章S-T(本章第232.405條)規定的每個交互式數據文件。
在勾選標記處表示註冊人是大型加速提交人、加速提交人、非加速提交人、小型報告公司還是新興增長公司。請參閱證券交易法120億條規則中「大型加速提交人」、「加速提交人」、「小型報告公司」和「新興增長公司」的定義。
大型加速文件提交人 | ☐ | 加速文件提交人 | ☐ |
☒ | 小型報告公司 | ||
新興成長公司 |
如果是新興成長公司,請勾選,如果註冊人已選擇不使用根據交易所法案第13(a)條提供的任何新的或修改的財務會計準則的延長過渡期,請勾選。
請勾選適用的圓圈,表示註冊登記者是否是空殼公司(根據交易所法案第12b-2條的定義)。是 ☐ 否
截至2024年11月14日,註冊人持有 流通中的A類普通股股份。
目錄
頁面 | ||
關於前瞻性聲明的註釋 | 3 | |
第一部分 - 財務信息 | ||
項目 1 | 基本報表 | 4 |
2024年9月30日的彙總資產負債表(未經審計)和2024年6月30日的彙總資產負債表 | 5 | |
截至2024年和2023年9月30日的三個月和六個月的合併損益及綜合收益表(未經審計) | 6 | |
2024年9月30日及2023年未經審計凝聚聯合股東赤字變動報表 | 7 | |
截至2024年9月30日未經審計的六個月內現金流量綜合表與2023年(未經審計) | 8 | |
未經審計的合併財務報表註釋。 | 9 | |
項目 2 | 管理討論和分析財務狀況及業績結果 | 19 |
項目 3 | 有關市場風險的定量和定性披露 | 22 |
項目 4 | 控制和程序 | 22 |
第二部分-其他信息 | ||
項目 1 | 法律訴訟 | 23 |
項目 1A | 風險因素 | 23 |
項目 2 | 未註冊的股票股權銷售和籌款用途 | 23 |
項目 3 | 對優先證券的違約 | 23 |
項目 4 | 礦山安全披露 | 23 |
項目 5 | 其他信息 | 23 |
項目 6 | 展示資料 | 24 |
簽名 | 25 |
2 |
關於前瞻性聲明的註釋
除了 有關歷史信息,這份10-Q表季度報告包含私人報告所指的前瞻性陳述 1995 年證券訴訟改革法。本10-Q表季度報告中包含的所有報表,歷史陳述除外 事實,包括有關我們未來經營業績和財務狀況的陳述、我們的業務戰略和計劃以及我們的 未來運營的目標是前瞻性陳述。「相信」、「可能」、「將」 這幾個字 「估計」、「繼續」、「預測」、「打算」、「期望」 和類似的表達 旨在識別前瞻性陳述。我們的這些前瞻性陳述主要基於我們當前的預期 以及我們認爲可能影響我們的財務狀況、經營業績、業務戰略的未來事件和趨勢的預測, 短期和長期的業務運營和目標以及財務需求。這些前瞻性陳述受數字約束 風險、不確定性和假設。此外,我們在競爭激烈且瞬息萬變的環境中運營。新的風險出現 不時。我們的管理層無法預測所有風險,也無法評估所有因素對我們業務的影響 或任何因素或因素組合在多大程度上可能導致實際結果與任何因素所含結果存在重大差異 我們可能做出的前瞻性陳述。鑑於這些風險、不確定性和假設,討論了未來的事件和趨勢 在本10-Q表季度報告中,可能不會出現,實際結果可能與預期的結果存在重大和不利的差異或 前瞻性陳述中暗示。
除非另有明示或上下文另有要求,在本文件中「Landbay」、「公司」、「我們」和「我們的」均指紐約公司Landbay Inc。鑑於存在這些風險和不確定性,讀者被告誡不要過分依賴這些前瞻性陳述。我們不承擔任何修訂這些前瞻性陳述並公開發布修訂結果的義務,除非法律要求這樣做。
除非 明確說明或上下文另有要求,「抗衰老」、「公司」、「我們」、「我們」 等術語 本文檔中的 「我們的」 是指紐約的一家公司Antiaging Quantum Living Inc.
3 |
部分I—財務信息
項目1.基本報表
基本報表索引
2024年9月30日的簡明綜合資產負債表(未經審計)和2024年3月31日的基本報表 | 5 |
截至2024年和2023年9月30日的三個月和六個月的合併損益及綜合收益表(未經審計) | 6 |
2024年9月30日及2023年未經審計凝聚聯合股東赤字變動報表 | 7 |
2024年9月30日和2023年的六個月簡明綜合現金流量表(未經審計) | 8 |
未經審計的合併財務報表註釋。 | 9-18 |
4 |
抗衰老量子生活公司(前稱阿奇森公司)
簡明合併資產負債表
截至2024年9月30日和2024年3月31日
九月三十日 | 3月31日, | |||||||
2024 | 2024 | |||||||
(未經審計) | (已審計) | |||||||
資產 | ||||||||
流動資產 | ||||||||
現金及現金等價物 | $ | $ | ||||||
應收賬款,淨額 | ||||||||
預付款項 | ||||||||
其他應收款和流動資產 | ||||||||
流動資產合計 | ||||||||
非流動資產 | ||||||||
物業、廠房及設備,淨值 | ||||||||
其他非流動資產 | ||||||||
經營租賃使用權資產,淨值 | ||||||||
非流動資產合計 | ||||||||
總資產 | ||||||||
負債和股東權益 | ||||||||
流動負債 | ||||||||
應付賬款和預提費用 | ||||||||
其他應付款 | ||||||||
由於關聯方 | ||||||||
應付稅款 | ||||||||
來自客戶的預付款 | ||||||||
經營租賃負債 - 流動部分 | ||||||||
總流動負債 | ||||||||
非流動負債 | ||||||||
經營租賃負債 - 非流動 | ||||||||
其他長期負債 | ||||||||
總非流動負債 | ||||||||
總負債 | ||||||||
承諾和或然事項 | ||||||||
股東權益 | ||||||||
A類普通股,$ | 面值; 授權股份, 已發行並在外流通的股份||||||||
B類普通股,$ | 面值; 授權股份, 已發行並在外流通的股份||||||||
C類普通股,$ | 面值; 授權股份, 已發行並在外流通的股份||||||||
D類普通股,$ | 面值; 授權股份, 已發行並在外流通的股份||||||||
E類普通股,$ | 面值; 授權股份, 已發行並在外流通的股份||||||||
額外實收資本 | ||||||||
累計虧損 | ( | ) | ( | ) | ||||
累計其他綜合(損失)收入 | ( | ) | ||||||
股東總虧損 | ( | ) | ( | ) | ||||
總負債和股東赤字 | $ | $ |
附帶說明
是這些未經審計的簡明合併基本報表的重要組成部分。
5 |
抗衰老量子生活公司(前稱阿奇森公司)
合併綜合收益表及全面收益表
截至2024年和2023年9月30日的三個月和六個月
未審計
截至三個月 | 截至六個月 | |||||||||||||||
九月三十日 | 九月三十日 | 九月三十日 | 九月三十日 | |||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
營業收入 | $ | $ | $ | $ | ||||||||||||
營業成本 | ||||||||||||||||
毛利潤 | ||||||||||||||||
營業費用: | ||||||||||||||||
銷售和市場費用 | ||||||||||||||||
一般及行政費用 | ||||||||||||||||
總營業費用 | ||||||||||||||||
運營損失 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
其他收入(支出): | ||||||||||||||||
利息收入 | ||||||||||||||||
其他總收入 | ||||||||||||||||
稅前虧損 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
所得稅費用 | ||||||||||||||||
淨損失 | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
加權平均流通股數 | ||||||||||||||||
基本和稀釋 | ||||||||||||||||
每股損失 | ||||||||||||||||
基本和稀釋 | $ | ) | $ | ) | $ | ) | $ | ) | ||||||||
其他全面收益(損失): | ||||||||||||||||
淨損失 | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
其他全面收益(損失): | ||||||||||||||||
外幣折算調整 | ( | ) | ( | ) | ||||||||||||
總綜合損失 | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) |
附帶的說明是這些的不可分割的一部分 未經審計的簡要 合併基本報表。
6 |
抗衰老 量子生活公司(前稱:阿奇森公司)
合併股東權益變動的簡明財務報表
截至2024年和2023年9月30日的六個月
未審計
A類 普通股 | B類 普通股 | C類 普通股 | D類 普通股 | E類 普通股 | 累計其他 | |||||||||||||||||||||||||||||||||||||||||||||||||||
數量 | 數量 | 數量 | 數量 | 數量 | 額外 實收資本 | 累計 | 綜合收入 | |||||||||||||||||||||||||||||||||||||||||||||||||
股份 | 金額 | 股份 | 金額 | 股份 | 金額 | 股份 | 金額 | 股份 | 金額 | 資本 | 赤字 | (虧損) | 總計 | |||||||||||||||||||||||||||||||||||||||||||
餘額 截至2023年3月31日 | $ | - | $ | - | $ | - | $ | - | $ | $ | $ | ( | ) | $ | $ | ( | ) | |||||||||||||||||||||||||||||||||||||||
股東 貸款取消 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
淨損失 | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||
餘額 截至2023年6月30日 | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||
淨損失 | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||
餘額 截至2023年9月30日 | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||
截至2024年3月31日的餘額 | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
淨損失 | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||
外幣 翻譯調整 | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||
截至2024年6月30日的餘額 | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||
淨損失 | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||
外幣 翻譯調整 | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||
截至2024年9月30日的餘額 | $ | - | $ | - | $ | - | $ | - | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) |
附帶的說明是這些未經審計的簡明合併基本報表的一個不可或缺的部分。
7 |
抗衰老 量子生活公司(前稱:阿奇森公司)
簡明合併現金流量表
截至2024年和2023年9月30日的六個月
未審計
六個月 結束 | ||||||||
九月三十日 | 九月三十日 | |||||||
2024 | 2023 | |||||||
經營活動產生的現金流 | ||||||||
淨損失 | $ | ( | ) | $ | ( | ) | ||
調整以將淨損失與用於 經營活動的淨現金進行調節 | ||||||||
折舊和攤銷費用 | ||||||||
運營租賃使用權資產的攤銷 | ||||||||
資產和負債的變化 | ||||||||
應收賬款增加 | ( | ) | ||||||
對供應商預付款的增加 | ( | ) | ( | ) | ||||
應收關聯方款項的增加 | ( | ) | ||||||
其他應收款和流動資產的增加 | ( | ) | ||||||
預收客戶款項的增加 | ||||||||
應付賬款和應計費用的增加 | ||||||||
其他應付款的增加 | ||||||||
合同負債減少 | ( | ) | ||||||
運營租賃負債增加 | ||||||||
淨現金流出活動 | ( | ) | ( | ) | ||||
投資活動產生的現金流量 | ||||||||
固定資產的購買 | ( | ) | ||||||
投資活動中使用的淨現金 | ( | ) | ||||||
融資活動產生的現金流 | ||||||||
來自股東貸款的收益 | ||||||||
來自關聯方應付款的收入 | ||||||||
融資活動提供的淨現金 | ||||||||
現金及現金等價物淨(減少)增加 | ( | ) | ||||||
貨幣兌換對現金及 現金等價物的影響 | ||||||||
現金及現金等價物 – 期初 | ||||||||
現金及現金等價物 – 期末 | $ | $ | ||||||
補充現金流量信息: | ||||||||
支付的利息 | $ | $ | ||||||
非現金融資和投資活動: | ||||||||
作爲額外實收資本的關聯方債務豁免 | $ | $ |
附帶的說明是這些未經審計的簡明合併財務報表的重要組成部分。
8 |
抗衰老 量子生活公司(前稱:阿奇森公司)
附註 未經審計的基本報表
(未經審計)
注意 1 - 組織和主要活動
抗衰老
量子生活公司(前稱:Achison公司)(「公司」、「我們」或「我們的」)根據州法成立
在2019年7月1日,Lansdale Inc("賣方"),一家由公司前任總裁謝萬軍先生控制的實體,與Dazhong 368 Inc("買方")簽訂了一份股票購買協議("協議"),根據該協議,
在2023年4月10日,Barry Wan先生獲得了對
關於此次交易,張定山先生於2023年4月10日辭去了他在公司的所有職務。2023年4月10日,吳靜女士被我們的主要股東任命爲首席執行官、財務長、總裁和董事。2023年6月16日,巴里·萬先生在吳靜女士辭職後同意擔任新任首席執行官和財務長。公司於2023年6月14日由新管理層更名爲抗衰老量子生活公司。該公司是一家投資控股公司;其主要業務運營通過其下屬公司進行,具體如下。
AAQL 公司(「BVI控股」)根據英屬維爾京群島的法律成立,作爲一家控股公司,負責管理所有板塊在美國以外的業務運營。
AAQL Hk Limited(「香港控股」)根據香港法律成立,作爲BVI控股的全資子公司。 香港控股的主要角色是作爲控股公司,專門監督亞太市場的業務活動。
抗衰老 杭州道靈醫生有限公司(「道靈醫生杭州」)於2023年11月13日在中國人民共和國法律下成立,作爲香港控股的全資子公司,主要營業地點位於浙江省杭州市蕭山區。其 主要業務是爲國內電子商務平台公司提供開發、事件;事件控制項和管理服務,提供個性化的營銷計劃、促銷策略,並收取「道靈醫生」品牌的使用費用。
道嶺醫生(浙江)健康管理有限公司(「道嶺醫生浙江」)於2023年11月30日在中華人民共和國法律下成立,作爲道嶺醫生杭州的全資子公司,主要營業地點位於浙江省杭州市。 其主要業務包括爲「道嶺醫生」品牌的分銷商提供專業的技術 事件控制項支持 和維護服務,並收取技術服務費用。
道靈醫生(湖州)健康管理有限公司(「道靈醫生湖州」)於2023年12月6日在中華人民共和國法律下成立,作爲道靈醫生杭州的全資子公司,主要營業地點位於浙江省湖州市。其 主要業務涉及提供健康諮詢服務(不包括診斷和治療服務)、網絡與信息安防軟件開發與大數據服務,以及其他服務。
抗衰老 量子生活公司及其子公司統稱爲「公司」。
9 |
注意 2 – 重要會計政策概要
展示基礎 合併原則
隨附的合併基本報表是根據美國通用會計準則(「U.S. GAAP」)編制的,包括所有子公司的資產、負債、收入、費用和現金流。 所有重要的公司之間的交易和餘額在合併時被消除。
管理層認爲,未經審計的臨時簡明基本報表反映了所有正常經常性性質的調整,這些調整對於公正地展示所呈現的臨時期間的結果是必要的。然而,這些基本報表中包含的經營業績結果可能不一定能夠反映年度結果。
該 公司在編制季度和年度基本報表時使用相同的會計政策。根據美國公認會計原則(「U.S. GAAP」),某些通常包含在年度基本報表中的信息和腳註披露已被簡化或省略。這些未經審計的簡化基本報表應與公司在2024年3月31日結束的年度報告(Form 10-k)中包含的經審計的基本報表及其附註一起閱讀,該報告已於2024年5月16日提交給證券交易委員會(「SEC」)。
估算的使用
附帶的基本報表是根據美國公認會計原則(「GAAP」)以及證券交易委員會(「SEC」)的規則和法規編制的。
公司的基本報表的編制遵循公認會計原則(GAAP),要求管理層進行估計、判斷和假設,這些都會影響基本報表及其附註中報告的金額。實際結果可能與這些估計和假設存在差異。
功能貨幣 和呈現貨幣
公司的功能貨幣是公司運營的主要經濟環境的貨幣,即人民幣(「RMB」)。人民幣不能自由兌換爲美元,並且可能受到中國貨幣限制,包括其子公司或可變利益實體向公司分配的分紅派息或留存收益。
交易所 以除實體功能貨幣之外的其他貨幣進行的交易,按交易發生日期的匯率記錄。 在每個報告期末,按外幣計量的貨幣項目按期末匯率進行換算。 在結算貨幣項目和期末換算貨幣項目時產生的匯率差額 被納入該期的損益表中。
爲了呈現這些基本報表,本公司的資產和負債按資產負債表日的匯率以美元表示,股東權益賬戶按歷史匯率翻譯,收入和費用項目按期間的加權平均匯率翻譯。 resulting translation adjustments 在股東權益(赤字)部分的資產負債表中的累計其他綜合收益(損失)項下報告。
用於翻譯的交易所匯率如下:
美元到人民幣 | 期間 結束 | 平均 | ||||||
2024年9月30日 | ||||||||
2024年3月31日 | ||||||||
2023年9月30日 | 不適用 | 不適用 |
10 |
現金 及現金等價物
現金 及現金等價物包括銀行現金、銀行存款以及在 發起日時到期在三個月內的高流動性投資。
應收賬款,淨額
公司將應收賬款以可變現淨值入賬,淨值爲賬面金額減去壞賬準備。壞賬準備是公司對可能發生的信用損失的最佳估計,基於公司現有的應收賬款。公司根據賬齡數據、歷史收款經驗、客戶特定情況以及經濟條件來確定壞賬準備。在經過所有收款手段無效後,會計餘額會計入壞賬準備,並且潛在的收回可能性被認爲極小。
預付款 給供應商
公司偶爾向供應商預付款,以確保未來貨物或服務的交付。這些預付款在資產負債表上記作資產,並在相關貨物收到時確認爲庫存,或在相關服務收到時確認爲費用。這些預付款主要與採購要銷售的庫存商品有關。
公司定期審查對供應商的預付款項的可回收性,並在必要時設立潛在損失的準備金。
資產 和設備
物業和設備以成本減去累計折舊後的淨值計入。改善相關資產功能或延長其使用壽命的支出會被資本化。當物業和設備被註銷或以其他方式處置時,相關的收益或損失會計入營業收入。租賃改善採用直線法在剩餘租賃期和資產估計使用壽命中的較短者上折舊。
物業 和設備按直線法在以下期限內進行折舊:
租賃改善 | ||||
辦公傢具和設備 |
長期資產的減值
公司已採用會計準則彙編子主題360-10,物業、廠房和設備(「ASC 360-10」)。ASC 360-10要求公司對持有和使用的長期資產以及某些可識別的無形資產進行減值評估,具體是在事件或環境變化表明資產的賬面價值可能不可收回時進行。公司每年或在事件和環境變化的情況下更加頻繁地評估其長期資產的減值。與可收回性相關的事件可能包括業務狀況顯著不利變化、持續虧損或預計無法在較長時間內實現盈虧平衡的經營結果。公司根據預測的未折現現金流量評估長期資產的可收回性。如果顯示出減值跡象,將根據資產使用和最終處置所產生的未來折現現金流量的估計調整無形資產的賬面價值。ASC 360-10還要求處置的資產按賬面價值與減去出售成本後的公允價值之間的較低者報告。
有
客戶 前進
公司在收到客戶預付款而未轉移商品時,將其記錄爲負債。這些預付款在滿足與之相關的履約義務時被確認作爲營業收入。這些預付款與客戶下訂單的商品預付款相關。
11 |
租賃
公司採用了FASB會計標準彙編,第842主題,租賃("ASC 842"),使用了修訂的追溯法,選擇了實用簡化方法,這允許公司在2019年1月1日標準採納之前不重述其比較期。
新的租賃標準要求在資產負債表上確認租賃作爲使用權(「ROU」)資產和租賃負債。 ROU資產代表公司在租賃期內使用基礎資產的權利,而租賃負債則代表公司因租賃而產生的租賃支付義務。營運租賃的ROU資產和營運租賃負債是基於租約開始日期的租賃期內的現值和未來最低租金支付進行確認的。公司用於判斷租賃負債的未來最低基於支付包括最低租金支付。由於大多數公司的租賃不提供隱含利率,故公司在判斷租賃支付的現值時使用基於開始日期可用信息的估算增量借款利率。公司沒有在資產負債表上確認任何 租期初始爲12個月或更短的租賃。
經營性 租賃成本在租賃期限內按直線法確認爲單一租賃成本。共同區域的 維護、房地產稅和其他營業費用的變動租賃支付在基於的事實和情況發生變化的期間確認計入費用。
營業收入 確認
營業收入 在我們將承諾的商品或服務的控制權轉移給客戶時確認,以反映我們期望獲得的對這些商品或服務的相應考慮金額。公司通過以下步驟確定營業收入的確認:1)識別與客戶的合同;2)識別合同中的履約義務; 3)確定交易價格;4)將交易價格分配給合同中的履約義務;5)在我們滿足履約義務時確認營業收入。
在線 廣告
該 公司運營一個在線廣告平台,將廣告主與出版商連接,以展示數字廣告。
對於公司而言,營業收入的確認發生在以下事件發生時:當客戶下訂單、收到付款,以及廣告交付並可供最終用戶查看且沒有其他條款和條件。
商品銷售
公司通過一個移動應用程序(「應用」)向客戶銷售健康和美容產品。
對於公司,營業收入的確認發生在以下事件發生時:當客戶下訂單、收到付款,以及貨物被交付給或直接發運並被客戶接受時。根據歷史退貨率和經驗,預計的銷售退貨會進行適當的準備,這些退貨是微不足道的。公司可能在客戶付款後但在客戶接受貨物之前,記錄合同負債,例如客戶預付款。
在線平台技術事件支持和 維護服務
公司爲其在線平台提供技術事件;事件控制項壓力位和 維護服務,確保平台功能、持續可用性及對用戶數的技術支持。
技術支持和維護服務的營業收入在提供服務期間內按比例確認,或在服務完成時確認。計費頻率可能有所不同(例如,每週、每月、每季度或完成時),具體取決於合同條款。每個計費週期或完成的服務期間代表一個獨立的履約義務,營業收入在該期間服務完成並開具發票時確認。
提供這些服務的主要直接成本是工資和薪金,這些都包含在銷售、一般和管理費用中。在預先收到款項的情況下,它們會被記錄爲合同負債(遞延營業收入),直到服務交付爲止。
對於每個營業收入來源,公司是主要方,因爲它在將特定的商品或服務轉讓給客戶之前控制這些商品或服務。作爲主要方,公司主要負責履行合同義務,擁有確定價格的自由裁量權,並承擔存貨或服務提供的風險,直至完成,因此每個營業收入來源的收入都是以毛額基礎進行確認。
銷售, 一般和管理費用
銷售、一般及行政費用主要包括與銷售和市場活動、行政職能及某些開始控制項成本相關的費用。
銷售 費用包括但不限於銷售佣金、廣告費用、交通和處理費用,以及與交易展覽和推廣活動相關的費用。一般和管理費用包括不直接參與生產的員工的薪資和福利、租金、公用事業費用、辦公用品、法律及專業費用、其他間接費用以及某些啓動費用。
啓動成本 代表與新業務建立相關的費用,包括市場調研、產品開發, 以及初始市場營銷活動。
公司在發生這些費用時予以確認,並始終與所產生的收入相匹配。
12 |
所得稅
公司採用資產和負債法記錄所得稅費用,用於遞延所得稅。在這種方法下,遞延稅款是基於法律法規和適用的法定稅率,按每年年底的資產和負債的稅基與其財務報告金額之間的差異,確認未來年度的稅務後果。如果基於現有證據,更可能是不會實現,遞延稅資產將按估值準備金減少。
當稅務申報表提交時,部分立場在稅務機關的審查中可能會被維持,而其他立場則存在對所採取立場的合理性或最終可能維持的立場金額的不確定性。稅務立場的利益會在基本報表中確認,確認的時期是在所有可用證據的基礎上,管理層認爲在審查時該立場更有可能被維持,包括上訴或訴訟程序(如有)的解決。所採取的稅務立場不會與其他立場相抵消或合併。符合更有可能被認可的稅務立場,被測量爲在與適用稅務機關解決時,稅務利益的最大金額,且有超過50%的可能性被實現。與所採取的稅務立場相關的利益部分超過上述金額時,會在附帶的資產負債表中反映爲未確認稅務利益的負債,以及任何相關的利息和罰款,這些將在審查時支付給稅務機關。與未確認稅務利益相關的利息被歸類爲利息支出,罰款被歸類爲運營報表中的一般和行政費用。
公司依據ASC第260主題《每股收益》計算基本和稀釋每股收益金額。基本每股收益是將可分配給普通股股東的凈利潤(虧損)除以報告期間普通股的加權平均股份數。稀釋每股收益反映如果期權和其他承諾行使或股權獎勵的歸屬導致發行普通股以共享公司收益時可能發生的稀釋。
截至2024年3月31日和2024年9月30日,公司沒有任何潛在的稀釋工具。
意外事件
Certain conditions may exist as of the date the financial statements are issued, which could result in a loss to the Company which will be resolved when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities, and such assessment inherently involves judgment. In assessing loss contingencies arising from legal proceedings pending against the Company or unasserted claims that may rise from such proceedings, the Company’s management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.
If the assessment of a contingency indicates it is probable a material loss will be incurred and the amount of the loss can be reasonably estimated, then the estimated loss is accrued in the Company’s financial statements. If the assessment indicates a material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed.
13 |
Fair Value Measurements
Fair value accounting establishes a framework for measuring fair value and expands disclosure about fair value measurements. Fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. This framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows:
● | Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. | |
● | Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments. | |
● | Level 3 inputs to the valuation methodology are unobservable and significant to the fair value. |
The Company’s financial instruments consisted of cash, accounts receivables, accounts payable, contract liabilities and loan from shareholders. The estimated fair value of those balances approximates the carrying amount due to the short maturity of these instruments.
Credit Losses on Financial Instruments
The Company recognizes credit losses on financial instruments in accordance with Accounting Standards Codification (ASC) Topic 326, Financial Instruments – Credit Losses. The Company uses the Current Expected Credit Losses (CECL) model to estimate credit losses on financial assets measured at amortized cost, as well as certain off-balance sheet credit exposures.
Under the CECL model, the estimation of credit losses involves significant judgment and estimation uncertainty. Management exercises its judgment based on historical loss experience, current economic conditions, and reasonable and supportable forecasts. Changes in these factors could have a material impact on the estimated credit losses.
Income Taxes
The Company accounts for income taxes using an asset and liability approach which allows for the recognition and measurement of deferred tax assets based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either expire before the Company is able to realize their benefits, or that future deductibility is uncertain.
Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred.
Recent Accounting Pronouncements
In March 2024, the FASB issued ASU 2024-01, Compensation – Stock Compensation. This ASU clarifies how to determine whether profits interest and similar awards should be accounted for as share-based payment arrangements. The ASU is effective in reporting periods beginning after December 15, 2024, including interim periods within the fiscal year, on a prospective or retrospective basis. Early adoption is permitted. The Company is currently evaluating the impact that adoption of this accounting standard will have on its consolidated financial statements and disclosures.
14 |
In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures. This ASU requires annual and interim disclosure of significant segment expenses that are provided to the CODM as well as interim disclosures for all reportable segment’s profit or loss and assets. This guidance also requires disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measures of segment profit or loss in assessing segment performance and deciding how to allocate resources. This guidance is expected to improve financial reporting by providing additional information about a public company’s significant segment expenses and more timely and detailed segment information reporting throughout the fiscal period. The ASU is effective for the Company’s fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that adoption of this accounting standard will have on its consolidated financial statements and disclosures.
In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU requires greater disaggregation of information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. This ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity’s exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. This ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. This ASU should be applied on a prospective basis although retrospective application is permitted. The Company is currently evaluating the impact that adoption of this accounting standard will have on its consolidated financial statements and disclosures.
There were other updates recently issued. The management does not believe that other than the disclosed above, accounting pronouncements the recently issued but not yet adopted will have a material impact on its financial position results of operations or cash flows.
NOTE 3 – GOING CONCERN
The
Company’s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement
of liabilities and commitments in the normal course of business. The Company had an accumulated deficit of $
Management’s plan to alleviate the substantial doubt about the Company’s ability to continue as a going concern include attempting to improve its business profitability, its ability to generate sufficient cash flow from its operations to meet its operating needs on a timely basis, obtain additional working capital funds from the majority shareholder and President of the Company to eliminate inefficiencies in order to meet its anticipated cash requirements. However, there can be no assurance that these plans and arrangements will be sufficient to fund the Company’s ongoing capital expenditures and other requirements.
The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.
NOTE 4 – ACCOUNTS RECEIVABLES
Accounts receivables, net comprised of the following:
September 30, 2024 | March 31, 2024 | |||||||
Accounts receivables | $ | $ | ||||||
Less: Allowance for doubtful accounts | ||||||||
Total, net | $ | $ |
There was
NOTE 5 – PROPERTY AND EQUIPMENT
Property and equipment, net comprised of the following:
September 30, 2024 | March 31, 2024 | |||||||
At Cost: | ||||||||
Leasehold improvements in progress | $ | $ | ||||||
Leasehold improvements | ||||||||
Office furniture and equipment | ||||||||
Total cost | ||||||||
Less: Accumulated depreciation | ( | ) | ( | ) | ||||
Total, net | $ | $ |
Depreciation
expenses was $
NOTE 6 – LOANS PAYABLE
The
Company has outstanding loans payable to unrelated third parties in the amount of $
15 |
NOTE 7 – RELATED PARTY TRANSACTIONS
Loan from shareholders
In
August 2019, the Company borrowed $
Upon
consummation of the change of control which resulted from that certain SPA entered into on April 10, 2023, the balance of the $
During
the six months ended September 30, 2024, the Company did not repay or received advances from Mr. Wan, our
President for working capital purpose. The outstanding amount due to Mr. Wan was $
During
the six months ended September 30, 2024, the Company borrowed funds in the amount of $
NOTE 8 – INCOME TAX
The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the period presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not.
United States
Hong Kong
Companies
incorporated in Hong Kong are subject to Hong Kong Profits Tax on the taxable income as reported in its statutory financial statements
adjusted in accordance with relevant Hong Kong tax laws. The applicable tax rate is
16 |
PRC
Effective
on January 1, 2008, the PRC Enterprise Income Tax Law, EIT Law, and Implementing Rules impose a unified enterprise income tax rate of
The following table summarizes the taxable income (loss) before income taxes by jurisdiction:
Six months
Ended September 30, | ||||||||
2024 | 2023 | |||||||
United States | $ | ( | ) | $ | ( | ) | ||
Hong Kong | ||||||||
China | ( | ) | ||||||
Total | $ | ( | ) | $ | ( | ) |
The following table summarizes a reconciliation of income tax expense for operations, calculated at the statutory income tax rate to total income tax expense (benefit):
Six months
Ended September 30, | ||||||||
2024 | 2023 | |||||||
Income tax expense at federal statutory rate | % | % | ||||||
Income tax expense at state statutory rate | % | % | ||||||
Income tax expense at PRC statutory rate | % | % | ||||||
Increases/(decreases) due to: | ||||||||
Foreign tax rate differential | % | % | ||||||
Change in valuation allowance | ( | )% | ( | )% | ||||
Effective tax rate | % | % |
NOTE 9 – SHAREHOLDERS’ EQUITY
The Company is authorized to issued shares of Class A common stock.
On March 28, 2023, the Company amended its article with New York State to change the authorized common shares with a par value of $ to shares, preferred shares.
During
the years ended March 31, 2024, a shareholder loan in the amount of $
On June 6, 2024, the Company amended its article with New York State to increase the authorized shares of common stock of the Company from thirty million ( ) shares of common stock, par value $ per share, to six billion ( ) shares of common stock, par value $ per share (the “Authorized Capital Increase”). Upon the effectiveness of the authorized shares increase, the shares of common stock will be categorized as follows: Class A shares, Class B shares, Class C shares, Class D shares, and Class E shares.
NOTE 10 – DISAGGREGATION OF REVENUE
The Company disaggregates its revenue by major revenue streams, as the Company believes this disaggregation best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows are affected by economic factors.
Six months Ended September 30, | ||||||||
2024 | 2023 | |||||||
Online advertising | $ | $ | ||||||
Sales of goods (Health and beauty products) | ||||||||
Technical operation support and maintenance services | ||||||||
Total | $ | $ |
NOTE 11 – LEASES
The Company has two operating leases for its office space.
Operating
lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease
term. The discount rate used to calculate present value is incremental borrowing rate or, if available, the rate implicit in the lease.
The Company determines the incremental borrowing rate for each lease based primarily on its lease term in PRC which is approximately
17 |
Operating
lease expenses were $
The components of lease expense and supplemental cash flow information related to leases for the period are as follows:
Six months
Ended September 30, | ||||||||
2024 | 2023 | |||||||
Lease cost | ||||||||
Operating lease cost | $ | $ | ||||||
Other Information | ||||||||
Cash paid for amounts included in the measurement of lease liabilities | $ | $ | ||||||
Weighted average remaining lease term – operating leases (in years) | - | |||||||
Average discount rate – operating lease | % | % |
The supplemental balance sheet information related to leases is as follows:
September 30, 2024 | March 31, 2024 | |||||||
Operating leases | ||||||||
Right-of-use assets | $ | $ | ||||||
Operating lease liabilities | $ | $ |
The undiscounted future minimum lease payment schedule as follows:
For the year ending March 31, | ||||
2025 (6 months remaining) | ||||
Thereafter | ||||
Total undiscounted lease payments | ||||
Less: interest | ( | ) | ||
Total lease liabilities |
NOTE 12 – SUBSEQUENT EVENTS
The Company evaluated all events or transactions that occurred after September 30, 2024 through the date the financial statements were issued. During the period, the Company did not have any material recognizable subsequent events required to be disclosed or adjusted as of and for the six months ended September 30, 2024.
18 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This Quarterly Report on Form 10-Q contains forward-looking statements, particularly those identified with the words, “anticipates,” “believes,” “expects,” “plans,” “intends,” “objectives,” and similar expressions. These statements reflect management’s best judgment based on factors known at the time of such statements. The reader may find discussions containing such forward-looking statements in the material set forth under “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” generally, and specifically therein under the captions “Liquidity and Capital Resources” as well as elsewhere in this Quarterly Report on Form 10-Q. Actual events or results may differ materially from those discussed herein. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict and no representation, guarantee, or warranty is to be inferred from those forward-looking statements. The assumptions used for purposes of the forward-looking statements specified in the following information represent estimates of future events and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives require the exercise of judgment. To the extent that the assumed events do not occur, the outcome may vary substantially from anticipated or projected results, and, accordingly, no opinion is expressed on the achievability of those forward-looking statements. No assurance can be given that any of the assumptions relating to the forward-looking statements specified in the following information are accurate, and we assume no obligation to update any such forward-looking statements.
Overview
Antiaging Quantum Living Inc. (FKA: Achison Inc.) (the “Company”, “us”, “we” or “our”) was incorporated under the laws of the State of New York on December 29, 2014.
On July 1, 2019, Lansdale Inc., the principal stockholder of the Company (“Seller”) and an entity controlled by the Company’s former President, Mr. Wanjun Xie, entered into a Stock Purchase Agreement (the “Agreement”) with Dazhong 368 Inc., (the “Buyer”), pursuant to which, a total of 9,000,000 shares of Class A common stock of the Company were transferred to the Buyer, representing approximately 90% of the Company’s issued and outstanding shares of Class A common stock, resulting in a change of the control of the Company. Mr. Dingshan Zhang was appointed as the President and CEO of the Company on the same date.
On April 10, 2023, Mr. Barry Wan acquired control of 29,215,000 restricted shares of Class A common stock (the “Purchased Shares”) of the Company, representing approximately 97% of the Company’s total issued and outstanding common stock from Dazhong 368 Inc and Sophia 33 Inc, two New York corporations controlled by the Company’s then President, Chief Executive Officer and sole director, Dingshan Zhang (the former President) pursuant to the terms of a Stock Purchase Agreement by and among the parties thereto (the “Stock Purchase Agreement”). Pursuant to the Stock Purchase Agreement, Mr. Wan paid an aggregate purchase price of four hundred thousand dollars ($400,000.00) to Mr. Zhang in exchange for the purchased shares. The foregoing transaction resulted in a change of control of the Company, with Mr. Wan acquiring 97% of the Company’s outstanding Class A common stock held through New Lite Ventures LLC, a New York LLC. Both before and after the transactions, the Company had 29,995,000 shares of its Class A common stock outstanding.
In connection with the transaction, on April 10, 2023, Mr. Dingshan Zhang resigned from all positions he held with the Company. On April 10, 2023, Ms. Jing Wan was appointed by our majority shareholder as our Chief Executive Officer, Chief Financial Officer, President and Director. On June 16, 2023, Mr. Barry Wan consented to act as the new Chief Executive Officer and Chief Financial Officer after Ms. Jing Wan resigned. The Company changed its name to Antiaging Quantum Living Inc. on June 14, 2023.
19 |
The change in control with respect to the Company was effectuated to better reflect its new business direction, with the intention of acquiring businesses involved in healthcare management and insurance services.
In line with this expansion, the Company established AAQL Inc. AAQL HK Limited Dao Ling Doctor Hangzhou, Dao Ling Doctor Zhejiang, and Dao Ling Doctor Huzhou entities.
On July 25, 2024, the Board of Directors of the Company approved the appointment of J&S Associate PLT to be the new independent registered public accounting firm for the financial period ending June 30, 2024. This appointment addressed the vacancy created by the resignation of PWN LLP as the Company’s former independent registered public accounting firm.
On September 6, 2024, the holders of a majority of the issued and outstanding voting securities of the Company approved an amendment to its Certificate of Incorporation increase in the number of authorized shares of common stock of the Company from thirty million (30,000,000) shares of common stock, par value $0.001 per share, to six billion (6,000,000,000) shares of common stock, par value $0.00001 per share (the “Authorized Capital Increase”). Upon the effectiveness of the Authorized Capital Increase, the shares of common stock will be categorized as follows: 1,200,000,000 Class A shares, 1,200,000,000 Class B shares, 1,200,000,000 Class C shares, 1,200,000,000 Class D shares, and 1,200,000,000 Class E shares. On the same day, the Certificate of Amendment to the Certificate of Incorporation of the Company was filed with New York State Department effectuating the Authorized Capital Increase.
Results of Operation for the three months ended September 30, 2024 and 2023
2024 | 2023 | $ Changed | % Changed | |||||||||||||
Revenue | 173,174 | - | 173,174 | 100.00 | % | |||||||||||
Cost of revenues | 14,373 | - | 14,373 | 100.00 | % | |||||||||||
Selling, general and administrative expenses | 356,569 | 24,378 | 332,191 | 1362.67 | % | |||||||||||
Loss from operations | (197,768 | ) | (24,378 | ) | (173,390 | ) | 711.26 | % | ||||||||
Other income (loss) | 22 | - | 22 | 100.00 | % | |||||||||||
Net loss | (197,746 | ) | (24,378 | ) | (173,368 | ) | 711.17 | % |
During the three months ended September 30, 2024 and 2023, the Company generated revenue in the amount of $173,174 and $nil, respectively. During the three months ended September 30, 2024 and 2023, the Company incurred operating expenses of $356,569 and $24,378, respectively. The increase in revenues and costs are related to the sales of health and beauty products which commenced since October 1, 2023. The Company also generated revenues in the amounts of $110,946 for its online platform technical operation support and maintenance services during the three months ended September 30, 2024.
The increase in operating expenses was mainly due to the increase in rental expenses and employee wages and benefits, which are related to the Company’s initiative for business expansion and additional revenue stream. The Company also incurred start-up costs such as cloud hosting expenses, development and maintenance costs in pursuit of its business plan.
For the three months ended September 30, 2024, our net loss was $197,746 comparing to a net loss of $24,378 for the three months ended September 30, 2023. The increase in net loss is mainly due to the increased operating expenses.
Results of Operation for the six months ended September 30, 2024 and 2023
2024 | 2023 | $ Changed | % Changed | |||||||||||||
Revenue | 375,243 | 1,200 | 374,043 | 31170.25 | % | |||||||||||
Cost of revenues | 14,538 | - | 14,538 | 100.00 | % | |||||||||||
Selling, general and administrative expenses | 772,405 | 55,305 | 717,100 | 1296.63 | % | |||||||||||
Loss from operations | (411,701 | ) | (54,105 | ) | (357,596 | ) | 660.93 | % | ||||||||
Other income (loss) | 47 | - | 47 | 100.00 | % | |||||||||||
Net loss | (411,654 | ) | (54,105 | ) | (357,549 | ) | 660.84 | % |
During the six months ended September 30, 2024 and 2023, the Company generated revenue in the amount of $375,243 and $1,200, respectively. During the six months ended September 30, 2024 and 2023, the Company incurred operating expenses of $772,405 and $55,305, respectively. The increase in revenues and costs are related to the sales of health and beauty products which commenced since October 1, 2023. The Company also generated revenues in the amounts of $251,507 for its online platform technical operation support and maintenance services during the six months ended September 30, 2024.
The increase in operating expenses was mainly due to the increase in rental expenses and employee wages and benefits, which are related to the Company’s initiative for business expansion and additional revenue stream. The Company also incurred start-up costs such as cloud hosting expenses, development and maintenance costs in pursuit of its business plan.
For the six months ended September 30, 2024, our net loss was $411,654 comparing to a net loss of $54,105 for the six months ended September 30, 2023. The increase in net loss is mainly due to the increased operating expenses.
20 |
Equity and Capital Resources
As of September 30, 2024, we had an accumulated deficit of $1,100,957; cash of $37,403; and a working capital deficit of $986,427, compared to accumulated deficit of $689,303; cash of $166,552 and a working capital deficit of $647,227 as of March 31, 2024.
The increase in the working capital deficit was primarily driven by a rise in other receivables and current assets, an increase in account receivable, increased advances to suppliers, a increase in accounts payable and accrued expenses, and an increase in other payables, which affected available cash.
The Company’s net loss was partially offset by non-cash expenses, including $71,921 in depreciation and $150,385 in amortization related to right-of-use (ROU) assets, mainly associated with leased office spaces and leasehold improvements.
For the six months ended September 30, 2024, the Company purchased fixed assets totalling $44,820 and received advances of $138,745 from related parties for working capital. These advances are currently not due for repayment, and the shareholders are prepared to continue providing funding as needed.
As of September 30, 2024, we held approximately $37,403 in cash and cash equivalents and did not have any outstanding bank loans. Our liabilities are primarily funded by shareholder loans, which do not require immediate repayment. Operations are continuing as usual, and management is committed to implementing expense control measures in the near term to support liquidity.
Going Concern Assessment
The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern. These adverse conditions are negative financial trends, specifically cash outflow from operating activities, operating losses, accumulated deficit and other adverse key financial ratios.
Management’s plan to alleviate the substantial doubt about the Company’s ability to continue as a going concern include attempts to consummate a business combination and to generate sufficient cash flow from its operations to meet its operating needs on a timely basis; as well as to obtain additional working capital funds as loans from the majority shareholder and the President of the Company.
21 |
The unaudited condensed and consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.
Critical Accounting Policies
The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires making estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
The critical accounting policies are discussed in further detail in the notes to the unaudited financial statements appearing elsewhere in this 10-Q report. Management believes that the application of these policies on a consistent basis enables us to provide useful and reliable financial information about our operating results and financial condition
Item 3. Quantitative and Qualitative Disclosures About Market Risk
As a “smaller reporting company” we are not required to provide this information under this item pursuant to Regulation S-K.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are designed with an objective of ensuring that information required to be disclosed in our periodic reports filed with the Securities and Exchange Commission, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission. Disclosure controls are also designed with an objective of ensuring that such information is accumulated and communicated to our management, including our chief executive officer, in order to allow timely consideration regarding required disclosures.
The evaluation of our disclosure controls by our principal executive officer included a review of the controls’ objectives and design, the operation of the controls, and the effect of the controls on the information presented in this Annual Report. Based on our management’s evaluation, our Chief Executive Officer, have concluded that as of such date, our disclosure controls were not, in design and operation, effective at a reasonable assurance level due to the material weaknesses in internal control over financial reporting. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Also, projections of any evaluation of the disclosure controls and procedures to future periods are subject to the risk that the disclosure controls and procedures may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
22 |
As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that there were material weakness in our internal controls over Financial reporting as of September 30, 2024 and they were therefore not as effective as they could be to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. The material weakness in our controls and procedure were lack of US GAAP knowledge and segregation duties. Management does not believe that any of these material weaknesses materially affected the results and accuracy of its financial statements. However, in view of this discovery of such weaknesses, management has begun a review to improve them.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 under the Exchange Act that occurred during the quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II – OTHER INFORMATION
Item 1. Legal Proceedings.
None
Item 1A. Risk Factors.
As a “smaller reporting company”, we are not required to provide this information under this item pursuant to Regulation S-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None
Item 3. Defaults Upon Senior Securities
None
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None
23 |
Item 6. Exhibits
* Incorporated by reference to the Company’s Registration Statement on Form S-1 as filed with the SEC on May 2, 2016.
** Filed herewith.
24 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ANTIAGING QUANTUM LIVING INC | |
Date: November 14, 2024 | /s/ Barry Wan |
Barry Wan, Chief Executive Officer | |
Date: November 14, 2024 | /s/ Barry Wan |
Barry Wan, Chief Financial Officer |
25 |